Multimeric antimicrobial peptide complex which is displayed on cell surface

ABSTRACT

The present invention provides an antimicrobial peptide polymer comprising at least one monomer which is digested by pepsin, a multimeric antimicrobial peptide complex comprising the polymer and a cell surface anchoring motif linked to the polymer, an antimicrobial microorganism displaying the multimeric antimicrobial peptide complex, an antimicrobial composition comprising the same, a method of treating an infectious disease caused by bacteria, yeast or fungi by administering the antimicrobial composition, and a method for producing the antimicrobial microorganism. According to the invention, living microorganisms displaying an antimicrobial peptide on the cell surface thereof may be administered in vivo without having to lyse the microbial cell and isolate and purify the antimicrobial peptide, so that the antimicrobial peptide exhibits antimicrobial activity. Thus, the antimicrobial peptide may be produced at significantly reduced costs so that it may have widespread use.

TECHNICAL FIELD

The present invention relates to an antimicrobial peptide polymercomprising at least one monomer which is digested by pepsin, amultimeric antimicrobial peptide complex comprising the polymer and acell surface anchoring motif linked to the polymer, an antimicrobialmicroorganism displaying the multimeric antimicrobial peptide complex,an antimicrobial composition comprising the same, a method of treatingan infectious disease caused by bacteria, yeast or fungi byadministering the antimicrobial composition, and a method for producingthe antimicrobial microorganism.

BACKGROUND ART

To protect humans from pathogenic microorganisms, many antibiotics havebeen discovered, developed and used. However, the misuse of antibioticshas resulted in a rapid increase in antibiotic-resistant strains, andthus the number of usable antibiotics has been limited. For this reason,there has been a demand for novel substances which have activationmechanisms different from conventional antibiotics, exhibit activityagainst antibiotic-resistant microorganisms, do not cause problems onresistance and do not remain in vivo for a long period of time. Typicalcandidates capable of satisfying this demand include antimicrobialpeptides.

Unlike conventional antibiotics, antimicrobial peptides have potentantimicrobial activities against a wide range of microorganisms, arephysically and chemically stable in heat, acid or alkali and consist ofa small number of amino acids (5-50 amino acids). Thus, theseantimicrobial peptides have advantages in that they are easily degradedafter antimicrobial action so that they do not remain in vivo,indicating that they do not cause toxicity in vivo. Thus, theantimicrobial peptides can be used as next-generation antibioticsubstances and are highly applicable in industrial fields, including thepharmaceutical and food fields.

The present inventors previously developed antimicrobial peptides havingpotent antimicrobial activity against a wide range of microorganisms(Korean Patent Registration No. 0441402).

For industrial application of these antimicrobial peptides, methodscapable of producing large amounts of the antimicrobial peptides in acost-effective manner are by necessity required, but conventionalmethods for producing the antimicrobial peptides cannot provide largeamounts of the antimicrobial peptides in a cost-effective manner. Inother words, the use of a chemical synthesis method, which is aconventional method for peptide production has low economic efficiency,and when an antimicrobial peptide is produced from microorganisms usinggenetic engineering technology there are problems in that theantimicrobial peptide is expressed at a low level and showsantimicrobial activity against the host and in that the expressedantimicrobial peptide is easily degraded by proteinases in the host.

In addition, in order to highly express an antimicrobial peptide inmicroorganisms, a method of producing a desired peptide from hostmicroorganisms using a fusion partner without killing the host cells wasgenerally used in the prior art.

In the above method, in order to recover the antimicrobial peptide, itis required to lyse the host cell to obtain an insoluble fusion protein,digest the fusion protein and isolate and purify the antimicrobialpeptide using a chromatography or ion-exchange column. However, theabove method has a critical problem in that a large amount of theantimicrobial peptide is lost during the recovery process so that theyield thereof is significantly reduced, resulting in a significantincrease in the price of the antimicrobial peptide.

To overcome this problem, an attempt was made to fuse a cell surfacedisplay protein with an antimicrobial peptide to display theantimicrobial peptide on the cell surface. As a result, the cell lysisprocess could be omitted by displaying the antimicrobial peptide on thecell surface, but there were still problems in that the cell surfacedisplay protein must be treated with a separate enzyme in order toisolate the antimicrobial peptide and in that a chromatography orion-exchange column must be used to remove impurities.

In addition, there is a method in which an antimicrobial peptidedisplayed on the cell surface is used without any treatment in order toomit the process of isolating and purifying the antimicrobial peptide.However, this method has a serious problem in that the antimicrobialactivity of the antimicrobial peptide attached to the cell surface issignificantly reduced.

DISCLOSURE Technical Problem

Accordingly, the present inventors have made extensive efforts todevelop an antimicrobial peptide which exhibits antimicrobial activityin vivo, using living microorganisms expressing the same, withoutisolating and purifying the antimicrobial peptide. As a result, thepresent inventors have found that, when a multimeric antimicrobialpeptide complex comprising a monomer which is digested by pepsin isdisplayed on the cell surface of E. coli, the displayed antimicrobialpeptide exhibits antimicrobial activity in vivo without having toisolate and purify the antimicrobial peptide from the E. coli cells,thereby completing the present invention.

Technical Solution

In order to accomplish the above objects, the present invention providesa multimeric antimicrobial peptide complex comprising an antimicrobialpeptide polymer comprising at least one monomer which is digested bypepsin, and a cell surface anchoring motif linked to the polymer.

Another object of the present invention is to provide an antimicrobialpeptide polymer comprising at least one monomer which is digested bypepsin.

Still another object of the present invention is to provide apolynucleotide encoding the above multimeric antimicrobial peptidecomplex or polymer.

Still another object of the present invention is to provide arecombinant vector comprising the above polynucleotide.

Still another object of the present invention is to provide anantimicrobial microorganism displaying the multimeric antimicrobialpeptide complex on the cell surface thereof.

Still another object of the present invention is to provide anantimicrobial pharmaceutical composition and an antimicrobialover-the-counter (OTC) drug composition, which comprise, as an activeingredient, the above multimeric antimicrobial peptide complex orantimicrobial peptide polymer or an antimicrobial microorganismdisplaying the above multimeric antimicrobial peptide complex on thecell surface thereof.

Still another object of the present invention is to provide a method forproducing an antimicrobial microorganism displaying the above multimericantimicrobial peptide complex on the cell surface thereof.

Yet another object of the present invention is to provide a method fortreating an infectious disease caused by bacteria, yeast or fungi, themethod comprising administering the antimicrobial pharmaceuticalcomposition.

Advantageous Effects

According to the present invention, an antimicrobial peptide is producedso that it can show antimicrobial activity when living microorganismsdisplaying the antimicrobial peptide on the cell surface thereof areadministered in vivo without having to lyse cells and isolate and purifythe antimicrobial peptide. Thus, the antimicrobial peptide can beproduced at significantly reduced cost so that it can have widespreaduse. In addition, the multimeric antimicrobial peptide complex orantimicrobial peptide polymer of the present invention is digested bythe enzyme pepsin in vivo so that it is separated into monomericantimicrobial peptide units, and the separated monomeric antimicrobialpeptide units have high antimicrobial activity. Thus, the multimericantimicrobial peptide complex or antimicrobial peptide polymer of thepresent invention can be effectively used for the treatment of aninfectious disease caused by pathogenic bacteria, yeast or fungi, and asa substitute for conventional antibiotics.

DESCRIPTION OF DRAWINGS

FIG. 1 shows the principle of activation of antimicrobial microorganismsthat display a multimeric antimicrobial peptide complex of the presentinvention on the cell surface thereof.

FIG. 2 schematically shows a process for constructing the inventivemultimeric antimicrobial peptide complex that is displayed on the cellsurface.

FIG. 3 is an agarose gel image showing the size of a Lpp-OmpA-Hinge2LnDNA fragment.

FIG. 4 is a schematic view of the recombinant vector pLHn including theLpp-OmpA-Hinge2Ln DNA fragment inserted therein.

FIG. 5 is a SDS-PAGE image showing the size of the Lpp-OmpA-Hinge2Ln DNAfragment displayed on transformed E. coli, and

FIG. 6 is a confocal micrograph showing a multimeric microbial peptidedisplayed on the cell surface of transformed E. coli. “M” in FIG. 5represents a molecular weight standard marker; LH0 in FIGS. 5 and 6indicates the IPTG-induced expression of a cell surface anchoring motifalone, and the arrow in LH1, LH2 and LH3 indicates the IPTG-inducedexpression of the monomer, dimer and trimer of the antimicrobial peptideHinge2L linked to the cell surface anchoring motif.

FIG. 7 is a graphic diagram showing the antimicrobial activity of an E.coli strain expressing a multimeric antimicrobial peptide complex andshows the results of observation of the antimicrobial activities of themonomeric antimicrobial peptides LH0, LH1 and LH3 cleaved by pepsin,when the activity of E. coli BL21 (DE3) as a negative control, whichdoes not express the antimicrobial peptide, was defined as 0%, and theactivity of the synthesized monomeric antimicrobial peptide Hinge2L as apositive control was defined as 100%.

BEST MODE

To achieve the above-described objects, in one aspect, the presentinvention provides a multimeric antimicrobial peptide complex comprisingan antimicrobial peptide polymer and a cell surface anchoring motiflinked to the polymer, wherein the antimicrobial peptide polymercomprises at least one monomer represented by the following formula 1 or2:

N-terminus-[antimicrobial peptide-amino acid linker digested bypepsin]-C-terminus; and  Formula 1

N-terminus-[amino acid linker digested by pepsin antimicrobialpeptide]-C-terminus;  Formula 2

wherein the antimicrobial peptide does not comprise the amino acid usedin the linker.

In another aspect, the present invention provides an antimicrobialpeptide polymer comprising at least one monomer represented by formula 1or 2.

As used herein, the term “antimicrobial peptide polymer” refers to apolymer in which one or more monomers which are digested by pepsin arerepeatedly linked by the amino acid linker that is digested by pepsin,and the term “multimeric antimicrobial peptide complex” refers to amultimeric peptide complex which comprises a cell surface anchoringmotif linked to the antimicrobial peptide polymer so that it can bedisplayed on the cell surface of a microorganism when being expressed inthe microorganism.

As shown in FIG. 1, the multimeric antibacterial peptide complex of thepresent invention is separated into monomeric antimicrobial peptideunits having antimicrobial activity, because the amino acid linker thatis digested by pepsin in the monomeric antimicrobial peptide is digestedby the digestive enzyme pepsin in vivo. Thus, when living microorganismsthat display the multimeric antibacterial peptide are injected in vivowithout isolating or purifying the multimeric antibacterial peptide fromthe microorganisms, effects such as the elimination of pathogens and theactivation of immune cells can be induced directly in vivo by theantimicrobial activity of the antimicrobial peptide.

In the present invention, the monomer has an amino acid linker that isdigested by pepsin linked to the N-terminus or C-terminus of theantimicrobial peptide.

The antimicrobial peptide is a peptide or its derivative, whichpenetrates microbial cells to exhibit potent antimicrobial activityagainst a wide range of microorganisms, including bacteria or fungi, anddoes not include the amino acid sequence of the amino acid linker thatis digested by pepsin in order to prevent the antimicrobial peptide frombeing digested by pepsin.

In addition, the antimicrobial peptide may be a peptide havingantimicrobial activity or its derivative. Preferably, it may be anantimicrobial peptide or its derivative, which does not include theamino acid sequence of the amino acid linker that is digested by pepsin,among antimicrobial peptides disclosed in Korean Patent Registration No.0441402. More preferably, it may be an antimicrobial peptide having anyone amino acid sequence selected from among the amino acid sequences ofSEQ ID NOS: 9 to 24, or a derivative thereof. Even more preferably, itmay be an antimicrobial peptide having the amino acid sequence of SEQ IDNO: 9, or a derivative thereof.

The amino acid linker that is digested by pepsin consists of one or moreamino acids. Thus, it acts as a linker that links antimicrobial peptidesto each other by peptide linkage, and is digested by the enzyme pepsinin vivo so that the multimeric antimicrobial peptide complex isseparated into monomeric antimicrobial peptide units. The multimericantimicrobial peptide complex or antimicrobial peptide polymer of thepresent invention may include one or more monomers represented byformula 1 or 2. The number of the monomers that may be included in atransformed microorganism or a vector is not limited, but is preferably1-4.

In the present invention, both ends of the amino acid linker that isdigested by pepsin are linked to the end of the antimicrobial peptide bypeptide linkage. The amino acid linker consists of an amino acidsequence that enables the peptide linkage formed between the ends of thelinker and N-terminus of the antimicrobial peptide to be broken by theaction of the digestive enzyme pepsin.

Preferably, the amino acid linker that is digested by pepsin may consistof one or more amino acids selected from the group consisting of leucine(Leu), phenylalanine (Phe) and tyrosine (Tyr). For example, it mayconsist of one or more leucines, one or more phenylalanines, one or moretyrosines, or a combination thereof comprising one or more amino acids.Preferably, it may consist of one leucine, one phenylalanine or onetyrosine.

In one Example of the present invention, the pepsin-digested site of anantimicrobial peptide polymer linked to the C-terminus of anantimicrobial peptide by any amino acid linker was predicted using acomputer program. As a result, it was shown that a peptide linkageformed between the end of one leucine, phenylalanine or tyrosine of theamino acid linker and the N-terminus of the antimicrobial peptide wasbroken while the antimicrobial peptide polymer could be separated intomonomeric antimicrobial monomer units (Example 1).

In the present invention, the cell surface anchoring motif is linked tothe antimicrobial peptide polymer so that the multimeric antimicrobialpeptide complex is displayed on the cell surface of microorganisms.

The cell surface anchoring motif may be selected from the groupconsisting of outer membrane proteins, lipoproteins, autotranspoters,and S-layer of surface appendage. Preferably, it may be an outermembrane protein. More preferably, it may be an outer membrane proteinselected from the group consisting of an E. coli outer membrane proteinOmpA, an E. coli outer membrane protein OmpA linked to the leadersequence of E. coli lipoprotein, an E. coli outer membrane protein OmpS,an E. coli outer membrane protein LamB, an E. coli outer membraneprotein PhoE, an E. coli outer membrane protein OmpC, an E. coli outermembrane protein FadL, a Salmonella outer membrane protein OmpC, and aPseudomonas outer membrane protein OprF. Even more preferably, it may bea cell surface anchoring motif (Lpp-OmpA) of SEQ ID NO: 8 which consistsof E. coli outer membrane protein OmpA linked to the leader sequence ofE. coli lipoprotein.

In the Examples of the present invention, antimicrobial peptide polymersHinge2L₁, Hinge2L₂, Hinge2L₃ and Hinge2L₄, each consisting of amonomeric antimicrobial peptide (Hinge2L) having one leucine as an aminoacid linker that is digested by pepsin added to the C-terminus of anantimicrobial peptide, were constructed (Example 2), and multimericantimicrobial peptide complexes Lpp-OmpA-Hinge2L₁, Lpp-OmpA-Hinge2L₂,Lpp-OmpA-Hinge2L₃ and Lpp-OmpA-Hinge2L₄, each consisting of a cellsurface anchoring motif (Lpp-OmpA), having an amino acid sequence of SEQID NO: 8, connected to the N-terminus of an antimicrobial peptidepolymer, were constructed (Example 3).

In another aspect, the present invention provides a polynucleotide,which encodes the multimeric antimicrobial peptide complex orantimicrobial peptide polymer of the present invention, and arecombinant vector comprising the same.

In the present invention, the polynucleotide that encodes the multimericantimicrobial peptide complex or the antimicrobial peptide polymer is aDNA (deoxyribonucleic acid) or RNA (ribonucleic acid) strand which is anucleotide polymer consisting of nucleotide monomer units covalentlybonded to each other.

The polynucleotide encoding the multimeric antimicrobial peptide complexmay be a polynucleotide having any one of the nucleotide sequences ofSEQ ID NO: 25 (Lpp-OmpA-Hinge2L₂), SEQ ID NO: 26 (Lpp-OmpA-Hinge2L₃) andSEQ ID NO: 27 (Lpp-OmpA-Hinge2L₄).

In addition, the polynucleotide encoding the antimicrobial peptidepolymer may be a polynucleotide having any one of the nucleotidesequences of SEQ ID NO: 28 (Hinge2L₂), SEQ ID NO: 29 (Hinge2L₂) and SEQID NO: 30 (Hinge2L₄).

In the present invention, the recombinant vector is a means used tointroduce a DNA into a microbial host cell to produce a microorganismthat displays the multimeric antimicrobial peptide complex orantimicrobial peptide polymer of the present invention on the cellssurface thereof. The recombinant vector that is used in the presentinvention can be prepared by using a known expression vector, such as aplasmid vector, a cosmid vector or a bacteriophage vector. The vectorcan be easily prepared by those skilled in the art according to a knownmethod using DNA recombination technology.

The recombinant vector that is used in the present invention may be apGEM T-easy vector or a pET21c vector, and preferably a pET21c vector.

The recombinant vector of the present invention is a recombinant vectorto which a polynucleotide encoding the multimeric antimicrobial peptidecomplex or antimicrobial peptide polymer of the present invention isoperably linked. As used herein, the term “operably linked” means thatan expression control sequence is linked so as to control thetranscription and translation of a polynucleotide sequence encoding themultimeric antimicrobial peptide complex or antimicrobial peptidepolymer of the present invention. Specifically, it means that a readingframe is accurately maintained so that the polynucleotide sequence isexpressed under the control of the expression control sequence(including a promoter) to produce the multimeric antimicrobial peptidecomplex or antimicrobial peptide polymer that is encoded by thepolynucleotide sequence.

In still another aspect, the present invention provides an antimicrobialmicroorganism transformed with the recombinant vector to display themultimeric antimicrobial peptide complex on the cell surface thereof.

As used herein, the term “antimicrobial microorganism” refers to amicroorganism capable of displaying an antimicrobial peptide on the cellsurface thereof. The antimicrobial microorganism of the presentinvention functions to display the multimeric antimicrobial peptidecomplex, which can be cleaved into monomeric antimicrobial peptides bythe digestive enzyme pepsin in the cells, on the cell surface, so thatthe antimicrobial microorganism itself kills pathogens in vivo. Thus,the antimicrobial microorganism of the present invention can be used asa substitute for antibiotics.

As used herein, the term “transformation” means that a gene isintroduced into a host cell so that it can be expressed in the hostcell. As the transformed gene, any gene which is inserted in thechromosome of a host cell or located outside the chromosome may be usedwithout limitation, as long as it can be expressed in the host cell.

In addition, the gene is a polynucleotide capable of encoding thepolypeptide, and examples thereof include DNA and RNA. The gene may beintroduced in any form, as long as it can be introduced and expressed ina host cell. For example, the gene may be introduced into a host cell inthe form of an expression cassette that is a polynucleotide structureincluding all elements required for self-expression. The expressioncassette generally includes a promoter operably linked to the gene, atranscription termination signal, a ribosome binding site and atranslation termination signal. The expression cassette may be in theform of a self-replicable expression vector. In addition, the geneitself may be introduced into a host cell, or the gene may be introducedinto a host cell in the form of a polynucleotide structure and may beoperably linked to a sequence required for expression in the host cell.

The antimicrobial microorganism is a microorganism transformed with therecombinant vector, which comprises the polynucleotide encoding themultimeric antimicrobial peptide complex, so as to be able to displaythe multimeric antimicrobial peptide complex on the cell surfacethereof. Examples of the antimicrobial microorganism include Escherichiasp., Bacilus sp., Aerobacter sp., Serratia sp., Providencia sp., Erwiniasp., Schizosaccharomyces sp., Enterobacteria sp., Zygosaccharomyces sp.,Leptospira sp. Deinococcus sp., Pichia sp., Kluyveromyces sp. Candidasp., Hansenula sp., Debaryomyces sp., Mucor sp., Torulopsis sp.,Methylobacter sp., Salmonella sp., Bacillus sp., Streptomyces sp.,Pseudomonas sp., Brevibacterium sp., and Corynebacterium sp.microorganisms.

Preferably, the antimicrobial microorganism may be an Escherichia sp.microorganism, more preferably E. coli, and even more preferably E.coli. BL21(DE3).

In the Examples of the present invention, it was shown that an E. colistrain transformed with a recombinant vector comprising a polynucleotideencoding the multimeric antimicrobial peptide complex was constructed(Example 4), and the expression of the multimeric antimicrobial peptidecomplex in the transformed E. coli cells was induced by IPTG, afterwhich whether the multimeric antimicrobial peptide complex was displayedon the cell surface. As a result, it could be seen that the monomer,dimer and trimer of the antimicrobial peptide Hinge2L linked to the cellsurface anchoring motif were displayed on the cell surface of the E.coli strain (Examples 5 and 6).

In another aspect, the present invention provides an antimicrobialpharmaceutical composition comprising, as an active ingredient, themultimeric antimicrobial peptide complex, antimicrobial peptide polymeror antimicrobial microorganism of the present invention.

In still another aspect, the present invention provides a method fortreating an infectious disease caused by pathogenic bacteria, yeast orfungi, the method comprising administering the above antimicrobialpharmaceutical composition to a subject having the infectious disease.

In the present invention, pathogenic bacteria refers to anymicroorganisms, which invade living animals or plants and is parasiticthereon to cause a disease or harm to the animals or plants. Examples ofthe pathogenic bacteria include gram-positive bacteria and gram-negativebacteria. Preferably, the pathogenic bacteria may be gram-positiveStaphylococus aureus or gram-negative Escherichia coli.

In addition, examples of the pathogenic yeast and fungi include, but arenot limited to, Candida albicans, Aspergillus humigatus, Saccharomycescerevisiae and Cryptococcus neoformans.

In the present invention, the infectious disease caused by pathogenicbacteria may be cholera caused by Vibrio cholera; bacillary dysenterycaused by dysentery bacillus; pertussis caused by Bordetella pertussis;typhoid fever caused by Salmonella typhi; laryngeal diphtheria and nasaldiphtheria caused by Corynebacterium diphtheria; bubonic plague andpneumonic plaque caused by Yersinea pestis; scarlet fever, erysipeloid,septicemia and pyoderma caused by hemolytic Streptococci; pulmonarytuberculosis, joint tuberculosis, renal tuberculosis and tuberculousmeningitis caused by Mycobacterium tuberculosis; or bacterialgastroenteritis caused by Salmonella and Vibrio parahaemolyticus. Inaddition, the infectious disease caused by pathogenic yeast and fungimay be cryptococcosis, candidasis, dermatophytosis, superficial mycoses,meningitis, brain abscess, brain tumor, histoplasmosis, pneumocystispneumonia or aspergillosis.

As used herein, the term “treatment” refers to all actions that restoreor beneficially change the infection caused by pathogenic bacteria,yeast or fungi by administering the antimicrobial pharmaceuticalcomposition. As used herein, the term “subject” refers to all animals,including humans, who have or are at risk of developing the infectiousdisease caused by pathogenic bacteria, yeast or fungi.

The antimicrobial pharmaceutical composition of the present inventioncan be administered to a human subject suffering from an infectiousdisease caused by pathogenic bacteria, yeast or fungi in order to treatthe infectious disease.

The antimicrobial pharmaceutical composition of the present inventionmay be administered by any general route, as long as it can reach atarget tissue. Specifically, the pharmaceutical composition of thepresent invention may be administered intraperitoneally, intravenously,intramuscularly, subcutaneously, intradermal orally, intranasally,intrapulmonarily or intrarectally, but is not limited thereto. Inaddition, the pharmaceutical composition may be administered using anysystem capable of delivering the active ingredient to a target cell.

When the antimicrobial pharmaceutical composition comprising theantimicrobial microorganism of the present invention is administered invivo, the multimeric antimicrobial peptide complex displayed on the cellsurface of the antimicrobial microorganism is digested by the digestiveenzyme pepsin in vivo and separated into monomeric antimicrobial peptideunits having antimicrobial activity, indicating that the process ofisolating and purifying the antimicrobial peptide is not required. Inaddition, the antimicrobial peptide cleaved into monomeric units bypepsin has high antimicrobial activity, and thus can be effectively usedto eliminate pathogens.

In the Example of the present invention, an E. coli strain that displaysthe multimeric antimicrobial peptide complex on the cell surface thereofwas treated with pepsin, and then the antimicrobial activity of themonomeric antimicrobial peptide units separated by pepsin was measured.As a result, it could be seen that the monomeric antimicrobial peptidehad high antimicrobial activity against gram-positive Staphylococusaureus, gram-negative Escherichia coli and yeast Saccharomycescerevisiae (Example 6 and FIG. 7).

The antimicrobial pharmaceutical composition of the present inventionmay include pharmaceutically acceptable carriers. The antimicrobialpharmaceutical composition may be in the form of various oral orparenteral formulations. The antimicrobial pharmaceutical composition isformulated using conventional diluents or excipients, including fillers,extenders, binders, wetting agents, disintegrants, and surfactants.Solid formulations for oral administration include tablets, pills,powders, granules, capsules, etc. These solid formulations may beprepared by mixing at least one compound with one or more excipients,for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc.In addition, liquid formulations for oral administration include asuspension, a solution, an emulsion and a syrup, etc. In addition towater commonly used as a simple diluent and liquid paraffin, variousexcipients, for example, wetting agents, sweetening agents, flavors,preservatives, etc. may be included. Formulations for parenteraladministration include sterilized aqueous solutions, non-aqueoussolvents, suspending agents, emulsions, freeze-drying agents,suppositories, etc. Propylene glycol, polyethylene glycol, vegetableoils such as olive oil, injectable esters such as ethyl oleate, etc. maybe used as non-aqueous solvents and suspending agents. Bases forsuppositories may include witepsol, macrogol, tween 61, cacao butter,laurin butter, glycerinated gelatin, etc. In addition, the formulationmay comprise nutrients required for displaying the multimericantimicrobial peptide complex on the cell surface of the antimicrobialmicroorganism included in the antimicrobial pharmaceutical composition.

The antimicrobial pharmaceutical composition may have any oneformulation selected from the group consisting of a tablet, a pill,powder, granules, a capsule, a suspension, a solution, an emulsion, asyrup, a sterilized aqueous solution, a non-aqueous solution, asuspension, an emulsion, a lyophilized formulation, and a suppository.

The pharmaceutical composition of the present invention may beadministered in a pharmaceutically effective amount. As used herein, theterm “pharmaceutically effective amount” refers to an amount sufficientto treat diseases, at a reasonable benefit/risk, ratio applicable to anymedical treatment. The effective dosage level of the composition may bedetermined depending on the subject's type, the disease severity, thesubject's age and sex, the activity of the drug, sensitivity to thedrug, the time of administration, the route of administration, excretionrate, the duration of treatment, drugs used in combination with thecomposition, and other factors known in the medical field. Thepharmaceutical composition of the present invention may be administeredalone or in combination with other therapeutic agents, and may beadministered sequentially or simultaneously with conventionaltherapeutic agents. The composition can be administered in a single ormultiple dosage form. It is important to administer the composition inthe minimum amount that can exhibit the maximum effect without causingside effects, in view of all the above-described factors.

In order to treat an infectious disease caused by pathogenic bacteria,yeast or fungi, the pharmaceutical composition of the present inventionmay be used alone or in combination with surgery, hormonal therapy, drugtherapy and a biological reaction regulator.

In still another aspect, the present invention provides an antimicrobialover-the-counter (OTC) drug composition comprising the inventiveantimicrobial microorganism as an active ingredient. In other words, thepresent invention provides an OTC drug composition for preventing orameliorating an infectious disease caused by pathogenic bacteria, yeastor fungi.

In the present invention, the OTC drug composition may be used togetherwith other OTC drugs or OTC drug components and can be appropriatelyused according to conventional methods. The amount of active ingredientadded can be suitably determined according to the intended use(prophylactic or therapeutic treatment).

The OTC drug composition may be in the form of a disinfectant, showerfoam, a mouth wash, a wet tissue, a detergent soap, a hand wash, afiller for humidifiers, a facial mask, an ointment or a filler forfilters.

In still another aspect, the present invention provides a method forpreparing an antimicrobial composition that displays the multimericantimicrobial peptide complex of the present invention on the cellsurface thereof.

The preparation method according to the present invention comprises thesteps of: (a) preparing a recombinant vector comprising a polynucleotideencoding the multimeric antimicrobial peptide complex of the presentinvention; (b) introducing the recombinant vector into a host cell toobtain a transformant; and (c) culturing the transformant to induce theexpression of the multimeric antimicrobial peptide complex.

The step of transforming the host cell by introducing the recombinantvector comprising the DNA of the present invention may be performedusing any method known in the art. Examples of the transformation methodinclude, but are not limited to, transient transfection, microinjection,transduction, cell fusion, calcium phosphate precipitation,liposome-mediated transfection, DEAE dextran-mediated transfection,polybrene-mediated transfection, electroporation and the like.

The step of culturing the transformant to induce the expression of themultimeric antimicrobial peptide complex may be performed using anymethod known in the art. For example, the expression of the multimericantimicrobial peptide complex can be induced by IPTG in LB medium at 37°C. under aerobic conditions, which are general conditions for the growthof E. coli cells.

In one Example of the present invention, E. coli BL21 (DE3) wastransformed with each of the recombinant vectors pLH0, pLH1, pLH2 andpLH3 using a CaCl₂-based transformation method in order to express themultimeric antimicrobial peptide complex of the present invention(Example 4). As can be seen in FIG. 6, the multimeric antimicrobialpeptide complex was displayed on the cell surface of the E. coli strainstransformed with the recombinant vectors (FIG. 6).

The antimicrobial microorganism produced by the method of the presentinvention displays the pepsin-digested multimeric antimicrobial peptidecomplex on the cell surface thereof. Thus, when the antimicrobialmicroorganism is administered in vivo in a living state, the multimericantimicrobial peptide complex will be separated into monomericantimicrobial peptide units having antimicrobial activity by pepsin,indicating that the process of lysing the microbial cell and isolatingand purifying the antimicrobial peptide is not required. In addition,the separated antimicrobial peptide units exhibits high antimicrobialactivity, and thus can be effectively used to eliminate pathogens.

MODE FOR INVENTION

Hereinafter, the present invention will be described in further detailwith reference to examples and test examples. It is to be understood,however, that these examples are for illustrative purposes only and arenot intended to limit the scope of the present invention.

Example 1 Determination of Sequence of Amino Acid Linker that isDigested by Pepsin and Measurement of Antimicrobial Activity ofMonomeric Antimicrobial Peptide Comprising the Amino Acid Linker 1-1:Determination of Sequence of Amino Acid Linker that is Digested byPepsin

In order to prepare an antimicrobial peptide polymer which is separatedinto monomeric units by pepsin, antimicrobial peptide units (SEQ ID NO.9: RVVRQWPIGRVVRRVVRRVVR) of SEQ ID NO: 1 disclosed in Korean PatentRegistration No. 0441402 were linked to each other using any amino acidas a linker, thereby obtaining an antimicrobial peptide polymer. Then,the sequence of the amino acid linker that is digested by pepsin toseparate the peptide polymer into monomeric forms was determined usingthe computer program tool ExPAsy (Expert protein analysis system,Swiss). As a result, a peptide linkage formed between the C-terminus ofeach of leucine, phenylalanine and tyrosine and the N-terminus of theantimicrobial peptide was digested by pepsin, and each of the aminoacids was determined to be an amino acid linker that is digested bypepsin.

1-2: Measurement of Antimicrobial Activity of Monomeric AntimicrobialPeptide Having Amino Acid Linker that is Digested by Pepsin AddedThereto

The amino acid sequence of the antimicrobial peptide polymer obtained byadding the amino acid linker, which is digested by pepsin, to theantimicrobial peptide, was predicted using a program, and as a result,it was shown that pepsin acted downstream of leucine, phenylalanine andtyrosine. Based on this finding, for these three peptides, 95% pureantimicrobial peptides were obtained by chemical synthesis.

The antimicrobial activities of the prepared antimicrobial peptidesagainst microorganisms were measured by a 96-well microdilution minimalinhibitory concentration assay. Specifically, bacteria and fungi werecultured overnight in trypticase soy broth (TSB) at 37° C. and 30° C.,respectively, and then the cells were inoculated in fresh media andcultured for 2 hours to the exponential growth phase. Then, the cellswere diluted to a density of 10⁵ cells/ml, and 10 μl of the dilution wasseeded into each well of a 96-well plate, after which each well wastreated with 10 μl of the serially diluted antimicrobial peptides. The96-well plate was incubated for 12 hours, and the absorbance of eachwell was measured. Herein, the minimum concentration at which themicrobial cells could not grow was determined as the minimum inhibitoryconcentration. The results of the measurement are shown in Table 1below. In Table 1, Hinge2L, Hinge2F and Hinge2Y indicate theantimicrobial peptides obtained by adding leucine, phenylalanine andtyrosine to the antimicrobial peptide of SEQ ID NO: 9, respectively.

TABLE 1 Hinge2L Hinge2F Hinge2Y Staphylococus. aureus (G+) 2 μl 4 μl 8μl Escherichia. coli(G−) 2 μl 4 μl 8 μl Saccharomyces. serevisiae 2 μl 4μl 8 μl (Yeast)

As can be seen from the results in Table 1 above, the peptide comprisingleucine added to the antimicrobial peptide had the highest antimicrobialactivity of 2 μl/ml against gram-positive Staphylococus aureus,gram-negative Escherichia coli, and yeast Saccharomyces cerevisiae(Table 1).

Example 2 Preparation of Antimicrobial Peptide Polymer which is Digestedby Pepsin

A DNA fragment was constructed, which encodes the monomericantimicrobial peptide (Hinge2L) comprising the amino acid linker(leucine) that is digested by pepsin added to the C-terminus of theantimicrobial peptide as described in Example 1. The DNA vector wascloned into a vector. Specifically, PCR was performed using primers ofSEQ ID NO: 1 (5′-GAAGACCCCGTGTTGTTCGTCAGTGGCCGATTGGTCGTGTCGTTCGCCGTGTTGTTCG-3′) and SEQ ID NO: 2(5′-GGATGGATCCTAAGCACGCAGACGAACGACGCGACGAACAACACGGCGAACGACACG-3′),thereby obtaining a double-stranded DNA fragment encoding a monomericantimicrobial peptide (consisting of 22 amino acids) comprising theamino acid linker that is digested by pepsin leucine added to theC-terminus of the antimicrobial peptide of SEQ ID NO: 9. The PCRreaction was performed for 30 cycles, each consisting of DNAdenaturation at 94° C. for 30 sec, annealing at 56° C. for 30 sec andDNA synthesis at 72° C. for 30 sec. For cloning, the restriction enzymeBbsI recognition site (5′-GAAGAC(N)₂▾-3′,3′-CTTCTG(N)₆▴-5′) wasintroduced into the N-terminus of the monomeric antimicrobial peptide,and the FokI recognition site (5′-GGATG(N)₉▾-3′,3′-CCTAC(N)₁₃▴-5′) wasintroduced into the C-terminus.

Then, the obtained DNA fragment was inserted into a pGEM T-easy vector,and the resulting vector was named “pMBT-H”.

In addition, in order to construct an antimicrobial peptide polymer, theDNA fragment encoding the monomeric antimicrobial peptide Hinge2L,constructed by PCR, was digested with the restriction enzymes BbsI andFokI, and then inserted into a pMBT-H vector digested with therestriction enzyme BbsI, thereby constructing a pMBT-H₂ vectorcomprising two Hinge2L units linked thereto. In an identical process,pMBT-H₂, pMBT-H₄ . . . pMBT-H_(n) were constructed (FIG. 2).

Example 3 Construction and Cloning of DNA Fragment of AntimicrobialPeptide Polymer Linked to Cell Surface Anchoring Motif 3-1: Constructionand Cloning of Antimicrobial Peptide Polymer DNA Linked to Lpp-OmpA

In order for the antimicrobial peptide polymer to be displayed on thehost cell surface, a Lpp-OmpA DNA fragment serving as a cell surfaceanchoring motif was constructed, which has the nucleotide sequence ofSEQ ID NO: 7 comprising a portion of an E. coli outer membrane protein A(OmpA) attached to the leader sequence of E. coli lipoprotein and to thecell outer membrane. The Lpp-OmpA DNA fragment was cloned into a vector.

Specifically, in order to construct the Lpp-OmpA DNA fragment, primersof SEQ ID NO: 3 (5′-CGCCATATGAAAGCTACTAAACTGGTACTGGGCAACAACAATGGCCCGACC-3′), SEQ ID NO: 4 (5′-GCAAACACCGGAGAAACGCCGGTG-3′), SEQ ID NO: 5 (5′-TTCTCCGGTGTTTGCTGGCGGTGTTG-3′) and SEQ IDNO: 6 (5′-CGGGATCCTAGTGATGGTGATGGTGATGAACACGCAGTCT TCCACGGGTAG-3′) weresynthesized, recombinant PCR was performed using the genomic DNA of E.coli MG1655 as a template and the synthesized primers for 30 cycles,each consisting of DNA denaturation at 94° C. for 30 sec, annealing at54° C. for 30 sec and DNA synthesis at 72° C. for 90 sec, therebyobtaining a DNA fragment (369 nucleotides) encoding a Lpp-OmpApolypeptide consisting of 123 amino acids.

Then, in order to achieve effective cloning while preventing a change inamino acids from occurring during expression, C at position 321 of therestriction enzyme BbsI recognition site of the Lpp-OmpA DNA sequenceobtained by the recombinant PCR method was replaced with G, and C atposition 324 was replaced with T, thereby constructing a Lpp-OmpA DNAfragment (SEQ ID NO: 7). In order to clone the constructed Lpp-OmpA DNAfragment into a vector, the restriction enzyme NdeI recognition site(CATATG) was introduced into the N-terminus of Lpp-OmpA, and therestriction enzyme BbsI recognition site (5′-GAAGAC(N)₂ ▾-3′,3′-CTTCTG(N)₆▴-5′) was inserted into the C-terminus so that theantimicrobial peptide polymer DNA fragment constructed in Example 2could be linked, and the restriction enzyme BamHI recognition site(GGATCC) was also introduced into the C-terminus. In addition, His tagwas introduced in order to confirm expression.

The obtained DNA fragment was inserted into a pGEM T-easy vector, andthe resulting vector was named “pLO vector”. The pLO vector was digestedwith BbsI, and pMBT-Hn constructed in Example 2 was digested with therestriction enzymes BbsI and FokI to obtain the DNA fragment of theantimicrobial peptide polymer Hinge2Ln, which was then ligated with thepLO vector digested with the restriction enzyme, thereby constructingpLO-Hinge2Ln vectors (n indicates the number of monomeric antimicrobialpeptide Hinge2L units; FIG. 2) including the DNA fragment(Lpp-OmpA-Hinge2Ln) consisting of the antimicrobial peptide polymer DNAlinked to Lpp-OmpA.

3-2: Measurement of Size of Lpp-OmpA-Hinge2Ln DNA Fragment

In order to confirm whether the DNA fragment was cloned, the size of theLpp-OmpA-Hinge2Ln DNA fragment inserted in the pLO-Hinge2Ln vectorconstructed in Example 3-1 was measured.

Specifically, each of the pLO-Hinge2Ln vectors was treated with therestriction enzyme NotI, and the size of the Lpp-OmpA-Hinge2Ln DNAfragment inserted into each vector was measured. The results of themeasurement are shown in FIG. 3. For electrophoresis, 0.3 g of 1%agarose gel was added to 30 ml of 1×TBE (Tris, Boric acid, EDTA) bufferand boiled in a microwave oven. The solution was poured into a mold andallowed to stand for 30 minutes so as to be hardened. Then, 10 μl of aLpp-OmpA-Hinge2Ln DNA solution was added to 2 μl of 6× loading dye,loaded onto the gel, and electrophoresed at 100 V for 40 minutes. Then,the gel was stained in EtBr solution for 20 minutes and washed withwater for 15 minutes.

FIG. 3 is an electrophoresis image showing the sizes of theLpp-OmpA-Hinge2Ln DNA fragments. In FIG. 3, M represents a DNA sizemarker, and lanes LH0, LH1, LH2, LH3 and LH4 represent the size of theLpp-OmpA-Hinge2Ln DNA fragments. Specifically, LH0 represents Lpp-OmpA,and LH1, LH2, LH3 and LH4 presents the numbers of monomericantimicrobial peptide units linked to the cell surface anchoring motifLpp-OmpA, respectively.

As can be seen in FIG. 3, the multimeric antimicrobial peptide complex(Lpp-OmpA-Hinge2Ln DNA) comprising the antimicrobial peptide polymerlinked to the cell surface anchoring motif Lpp-OmpA was effectivelycloned into the vector (FIG. 3).

Example 4 Construction of Microorganism Displaying MultimericAntimicrobial Peptide Complex (Lpp-OmpA-Hinge2Ln) on Cell Surface

As shown in FIG. 4, the multimeric antimicrobial peptide complex and aHis tag were linked to Lpp-OmpA DNA, thereby constructing recombinantvectors. Specifically, each of the pLO-Hinge2Ln vectors constructed inExample 3 was treated with the restriction enzymes NdeI and BamHI toobtain Lpp-OmpA-Hinge2Ln DNA fragments, and DNA fragments having desiredsizes were separated therefrom using a gel extraction kit (Qiagen,Germany).

Each of the separated DNA fragments was linked to a pET21c vectordigested with NdeI and BamHI, thereby constructing pLHn (pLH0, pLH1,pLH2 . . . , n=number of Hinge2L monomers) vectors (FIG. 4). Then, eachof the pLH0, pLH1, pLH2 and pLH3 vectors was introduced into E. coliBL21 (DE3) by a CaCl₂-based transformation method.

Example 5 Examination of Whether Multimeric Antimicrobial PeptideComplex (Lpp-OmpA-Hinge2Ln) was Displayed on Cell Surface

Whether the multimeric antimicrobial peptide complex was displayed onthe cell surface of the transformed E. coli strain of the Example 4 wasexamined. Specifically, the transformed E. coli cells were cultured inLB medium (Luria Botani, 1% tryptone, 0.5% yeast extract, and 0.5%NaCl), and when the culture medium reached an OD₆₀₀ of 0.5-0.6, 0.2 mMIPTG (isopropyl-β-D-thiogalactopyranoside was added thereto to inducethe expression of the multimeric antimicrobial peptide complex on thecell surface. 4 hours after the induction of the expression, the mediumwas removed, and the cells were washed twice with PBS (phosphatebuffered saline), and 0.2% BSA (bovine serum albumin)-containing PBS andHis-tag primary antibody were to the cells which were then incubated onice for 30 minutes. After the incubation, the cells were washed twicewith PBS, and FITC conjugated His tag secondary antibody was added tothe cells which were then incubated on ice for 30 minutes underlight-shielded conditions. Then, the E. coli cells were washed with PBS,resuspended in PBS, and observed with a confocal microscope.

As a result, it was shown that the expression of the cell surfaceanchoring motif which was not linked to the monomeric antimicrobialpeptide was induced by IPTG (LH0), and the expressions of cell surfaceanchoring motif-monomeric antimicrobial peptide, cell surface anchoringmotif-dimeric peptide, and cell surface anchoring motif-trimeric peptidewere induced by IPTG (FIG. 5).

In addition, it could be seen that the multimeric antimicrobial peptidecomplexes LH1, LH2 and LH3 linked to the cell surface anchoring motifwere displayed on the cell surface of the transformed E. coli by IPTG(FIG. 6).

Example 6 Examination of Antimicrobial Activity of MultimericAntimicrobial Peptide Complex Displayed on Cell Surface

The antimicrobial effect of the E. coli strain, constructed in Example 4and displaying the multimeric antimicrobial peptide complex on the cellsurface, was measured. Specifically, the transformed E. coli BL21 (DE3)was cultured in 100 ml of LB medium, and when the culture medium reachedan OD₆₀₀ of 0.5-0.6, 0.2 mM IPTG was added thereto to induce theexpression of the multimeric antimicrobial peptide complex linked to thecell surface anchoring motif. 4 hours after the induction of theexpression, the medium was removed, and the cells were washed twice withNAPB (sodium phosphate buffer), and then resuspended in the same buffer.All the E. coli samples were adjusted to a cell number of 1×10¹⁰ cfu/ml.Then, pepsin was dissolved in simulated gastric fluid (SGF) (0.084 NHCl, 35 mM NaCl, pH 1.2 or 2.0), and the E. coli cells were treated withthe pepsin solution and incubated for 30 minutes. After the incubation,in order to deactivate pepsin and neutralize the pH, the sameconcentration of NaOH aqueous solution as that of the simulated gastricfluid was added to the cells, and the cell solution was centrifuged toremove cell debris other than the monomeric antimicrobial peptidedigested by pepsin.

The antimicrobial activities of the pepsin-digested monomericantimicrobial peptide against gram-positive Staphylococus aureus,gram-negative Escherichia coli and the yeast Saccharomyces cerevisiaewere measured.

Each of the microbial strains was collected in the exponential growthphase during the culture, washed twice with NAPB, and then resuspendedin the same buffer. The number of the microbial cells was adjusted to1×10⁵ cfu/ml. 10 μl of an aqueous solution containing each microbialstrain and the pepsin-digested monomeric antimicrobial peptide wasdispensed into each well of a 96-well plate, mixed well and incubated at37° C. for 3 hours. After 3 hours, 2×TSB (Trypticase Soy Broth) mediumwas added to the cells which were then incubated at 37° C. for 12 hours,after which the absorbance at OD₅₉₅ was measured.

As a result, among the multimeric antimicrobial peptide complexes, LH3showed antimicrobial activities of 17.95% against gram-positiveStaphylococus aureus, 30% against gram-negative Escherichia coli, and33.17% against yeast Saccharomyces cerevisiae, indicating that LH3showed the highest antimicrobial activity (FIG. 7). Such results suggestthat the antimicrobial activity of the multimeric antimicrobial peptidecomplex increases as the number of monomeric antimicrobial peptide unitstherein increases, and when antimicrobial microorganisms displaying thismultimeric antimicrobial peptide complex are administered in vivo, theycan show antimicrobial effects, including the elimination of pathogensand the activation of immune cells. Thus, it can be seen that theantimicrobial peptide can be used without having to isolate and purifythe antimicrobial peptide, suggesting that the antimicrobial peptide canhave widespread use.

1. An isolated multimeric antimicrobial peptide complex comprising anantimicrobial peptide polymer and a cell surface anchoring motif linkedto the polymer, wherein the antimicrobial peptide polymer comprises atleast one monomer represented by the following formula 1 or 2:N-terminus-[antimicrobial peptide-amino acid linker digested bypepsin]-C-terminus,  Formula 1N-terminus-[amino acid linker digested by pepsin-antimicrobialpeptide]-C-terminus,  Formula 2 wherein the antimicrobial peptide doesnot comprise the amino acid used in the linker.
 2. The isolatedmultimeric antimicrobial peptide complex of claim 1, wherein theantimicrobial peptide has any one of amino acid sequences represented bySEQ ID NOS: 9 to
 24. 3. The isolated multimeric antimicrobial peptidecomplex of claim 1, wherein the amino acid linker digested by pepsin isselected from the group consisting of leucine, phenylalanine andtyrosine.
 4. The isolated multimeric antimicrobial peptide complex ofclaim 1, wherein the cell surface anchoring motif is linked to theN-terminus of the polymer.
 5. The isolated multimeric antimicrobialpeptide complex of claim 1, wherein the cell surface anchoring motif isan outer membrane protein.
 6. The isolated multimeric antimicrobialpeptide complex of claim 5, wherein the outer membrane protein isselected from the group consisting of an E. coli outer membrane proteinOmpA, an E. coli outer membrane protein OmpA linked to the leadersequence of E. coli lipoprotein, an E. coli outer membrane protein OmpS,an E. coli outer membrane protein LamB, an E. coli outer membraneprotein PhoE, an E. coli outer membrane protein OmpC, an E. coli outermembrane protein Fad L, a Salmonella outer membrane protein OmpC, and aPseudomonas outer membrane protein OprF.
 7. The isolated multimericantimicrobial peptide complex of claim 6, wherein the E. coli outermembrane protein OmpA linked to the leader sequence of E. colilipoprotein has an amino acid sequence represented by SEQ ID NO:
 8. 8.The isolated multimeric antimicrobial peptide complex of claim 1,wherein the antimicrobial peptide has an amino acid sequence representedby SEQ ID NO: 9, the amino acid linker digested by pepsin is leucine,and the cell surface anchoring motif has an amino acid sequencerepresented by SEQ ID NO:
 8. 9. An isolated antimicrobial peptidepolymer comprising at least one monomer represented by the followingformula 1 or 2:N-terminus-[antimicrobial peptide-amino acid linker digested bypepsin]-C-terminus,  Formula 1N-terminus-[amino acid linker digested by pepsin-antimicrobialpeptide]-C-terminus,  Formula 2 wherein the antimicrobial peptide doesnot comprise the amino acid used in the linker.
 10. A polynucleotideencoding the isolated multimeric antimicrobial peptide complex ofclaim
 1. 11. A polynucleotide encoding the isolated antimicrobialpeptide polymer of claim
 9. 12. The polynucleotide of claim 10, whereinthe polynucleotide has any one of nucleotide sequences represented bySEQ ID NOS: 25 to
 27. 13. The polynucleotide of claim 11, wherein thepolynucleotide has any one of nucleotide sequences of SEQ ID NOS: 28 to30.
 14. A recombinant vector comprising the polynucleotide of claim 10.15. An antimicrobial microorganism transformed with the recombinantvector of claim 14 to display a multimeric antimicrobial peptide complexon the cell surface thereof.
 16. (canceled)
 17. An antimicrobialcomposition comprising the isolated multimeric antimicrobial peptidecomplex of claim 1 as an active ingredient.
 18. An antimicrobialcomposition comprising the isolated antimicrobial peptide polymer ofclaim 9 as an active ingredient.
 19. (canceled)
 20. The antimicrobialcomposition of claim 17, wherein the composition is a pharmaceuticalcomposition or an over-the-counter (OTC) drug composition.
 21. A methodfor producing an antimicrobial microorganism displaying a multimericantimicrobial peptide complex on the cell surface thereof, comprising(a) preparing a recombinant vector comprising a polynucleotide encodingthe isolated multimeric antimicrobial peptide complex of claim 1; (b)introducing the recombinant vector into a host cell to obtain atransformant; and (c) culturing the transformant to induce theexpression of the multimeric antimicrobial peptide complex.
 22. A methodfor treating an infectious disease caused by pathogenic bacteria, yeastor fungi, comprising administering the antimicrobial composition ofclaim 17 to a subject having the infectious disease.
 23. (canceled)